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Abstract 
Background: The aim of this work was evaluate the antioxidant effect of 
ascorbyl laurate (ASC12) based nanostructures applied topically to the cornea 
of ocular normotensive and hypertensive rabbits. The ASC12 was chosen for its 
capacity to form liquid lyotropic crystal and keeps its free radical trapping power. 
Methods: The hypertension model was performed in six rabbits and was 
obtained by the application of intracameral injections of alpha-chymotrypsin in 
the right eye. A single 50 mL dose of ascorbyl laurate coagel 2% w/v (COA-
ASC12)  was applied topically to the cornea of six normotensive and six 
hypertensive rabbits. The aqueous humor samples were obtained before and 
after instillation of COA-ASC12 at different times (2h and 4h). Antioxidant 
capacity was determined via the reduction reaction with iron and 
tripyridyltriazine (FRAP) and the total proteins were measured using the 
Bradford reagent. 
Results: The kinetic antioxidant capacity in the aqueous humor of normotensive 
and hypertensive rabbits showed a maxim increment at 4 hours instillation. 
Also, the antioxidant capacity in the aqueous humor of hypertensive rabbits was 
ten times lower than in normotensive rabbits.  
Conclusion: This type of nanostructures has the potential to significantly 

















The eye is an organ continuously exposed to ionizing radiation, 
pollutants, industrial smoke and conduction fumes, which makes the eyeballs 
very susceptible to oxidative attack. This is the product of an imbalance 
between the production of free radicals (RL) and the elimination of these by 
means of the antioxidant defenses commonly known as oxidative stress (EO) 
[1].  
To minimize oxidative stress, ocular tissues utilize a range of antioxidant 
defense systems, which include non-enzymatic and enzymatic antioxidants, 
however, as we age our antioxidant defense systems are overwhelmed, 
resulting in increased oxidative stress and damage to the tissues of the eye.  
Ascorbic acid (AA), commonly called vitamin C (VC), is considered one 
of the most potent antioxidant agents in the body and it is present in the human 
aqueous humor at a concentration of 1 mM. Although it is present in a wide 
variety of tissues, the corneal epithelium has the highest concentration of AA, 
indicating that this antioxidant is particularly important to protect this tissue from 
oxidative stress [2].  
According to the current literature it is likely that an imbalance between 
pro-oxidative factors and antioxidant capacity has been shown to play an 
important role in the pathogenesis of glaucoma and many of the markers of 
oxidative stress have been reported in glaucomatous disease [3,4].  
According to the WHO, glaucoma is the second leading cause of 
blindness in the world; it is a progressive optic neuropathy, often caused by 
elevated intraocular pressure (IOP) due to high abnormal resistance to the 
drainage of the aqueous humor through the trabecular meshwork and 
Schlemm's canal [5]. Normal regulation of IOP occurs chiefly through the 
regulation of the volume of the aqueous humor in the anterior chamber of the 
eye. This process depends on the balance of a complex mechanisms involved 
in the production and output of the aqueous humor, including the stability and 
survival of the cellular phenotypes involved in this process and the correct 
maintenance of homeostasis [6,7]. If ocular hypertension (OHT) persists for a 
long time, it causes irreversible damage to all ocular structures, resulting in a 
characteristic decrease in the visual field that concludes with optic nerve 












Glaucoma is usually treated with hypotensive agents and therefore the 
efficacy of these systems depends on the pharmacodynamics of the hypotensor 
and the ability of the drug to permeate the cornea and reach its site of action in 
time and form (pharmacokinetics). 
Topical administration of liquid dosage forms such as solutions is the 
most common strategy for treating ocular diseases, however it is well known 
that very fluid liquid formulations present several drawbacks to drug 
bioavailability, owing mainly to efficient eye mechanisms for drug removal from 
ocular surface. The development of more convenient pharmaceutical 
formulations becomes necessary in order to overcome this kind of limitation. 
In this context, the use of surfactants in pharmaceutical technology has 
been extensively explored. Depending on the chemical structure, concentration 
and temperature, surfactants are able to form supramolecular aggregates with 
particular properties according to the concentration increases. In these cases, 
interactions between adjacent structures increase and consequently the system 
can revert to bigger and more complex structures, usually called liquid crystals 
(CLs). CLs formed through interactions between the surfactant and the solvent 
are known as lyotropic liquid crystals (CLLs). 
They also retain the ability of AA to remove radicals, and their antioxidant 
effectiveness is comparable to other natural reducing agents, such as 
carotenes, polyphenols, and tocopherols. 
Our research group has explored the use of these derivatives as carrier 
systems without deepening the "per se" effect that this type of system may have 
in modifying the antioxidant capacity of aqueous humor [9]. 
Although it is well established that AA is important for protecting the 
ocular tissues from oxidative stress, there is no evidence of formulations of VC 
that can penetrate membranes to protect internal ocular structures that can be 
damaged in the glaucoma pathology. 
It is thus interesting to explore its permeation inside the eye and its 
potential effects on the antioxidant capacity of aqueous humor in normotensive 
animals and OHT models. 
 













(The samples were prepared and characterized as described by Palma et al. 
2006). 2% w/v aqueous suspensions (using isotonic and sterile dextrose 
solution (5 % w/v) as medium) of ASC12 were heated to 55°C to produce a 
self-assembly at a temperature higher than their critical micellar temperature 
(52.1 °C).  The samples were then cooled to room temperature to obtain coagel 
(COA-ASC12) The ASC12 has been selected for previous results already 
published [9,10].  
 
Animals 
Twelve New Zealand rabbits (IOP average=11.39±0.92 mmHg) weighing 2–
2.5kg were used. The rabbits were provided with food and water ad libitum in a 
temperature-controlled room (21°C±5°C) and exposed to 12h light: 12h dark 
cycles. In all cases, the appropriate measures were taken to minimize the 
discomfort and pain of the animals. The experiments were carried out following 
the CICC guidelines (FCM-UNC), coinciding with the Guidelines for the care 
and use of laboratory animals published by the National Institute of Health 
(NIH). This project has been approved by CICUAL - FCM - UNC (No. 44/2017). 
 
Hypertension model 
The OHT model was performed in six normotensive rabbits to simulate 
the characteristic conditions of the glaucoma disease. This model was obtained 
by the application of intracameral injections of alpha-chymotrypsin in the right 
eye (OD) [11]. 
Surgical technique: pilocarpine 2% w/v was instilled in the eye to cause 
miosis, then a paracentesis was performed and 0.1 ml of alpha chymotrypsin at 
a concentration of 3 mg/ml was injected into the anterior chamber using a 27-
gauge cannula. After 3 minutes, the eye was washed with physiological solution 
and topical antibiotic and nonsteroidal anti-inflammatory were applied. A volume 
of 0.1 ml of physiological solution was injected into the anterior chamber of the 
left eye, which was used as surgical control. The IOP values were determined 
before and after induction of OHT, every 5 days for 40 days with digital 
veterinary manual tonometer (ICARE®). All animals were anesthetized with 













Instillation of ascorbyl laurate based nanostructures in rabbit eyes 
A single 50 mL dose of COA-ASC12  was instilled topically to the surface 
of eye in six normotensive and six hypertensive rabbits.  
 
Determination of total antioxidant capacity 
The aqueous humor samples (200 μL with TERUMO syringes) were 
obtained before and after instillation of COA-ASC12 at different times (2h and 
4h). Upon completion of the examination, the animals were euthanized by CO2 
inhalation according to the protocol. 
Antioxidant capacity was determined via the reduction reaction with iron 
and tripyridyltriazine (FRAP) and the total proteins were measured using the 
Bradford reagent. Ten μL of aqueous humor was used. 300 μL of a mixture of 
reagents (10 parts of 300 mM acetate buffer pH 3.6, 1 part of 10 mM (2,4,6-
tripyridyl-s-triazine) TPTZ solution in 40 mM HCl and 1 part ferric chloride 
solution (FeCl3.6H2O) 20 mM were added). Aqueous solutions of known 
concentrations of Fe2 + (FeSO4.7H2O) were used as controls to perform the 
calibration curve and the final color was determined in a microplate reader (Bio-
Rad) at 595 nm. 
On the other hand, the determination of total proteins was carried out 
with the Bradford method. For this determination, 5 μl of sample was used, to 
which 250 μl of Bradford reagent was added and it was read 
spectrophotometrically at 595 nm.  




Statistical  analysis 
Data was expressed as means and standard deviations. The results 
were analyzed using Student's t-test (individual times) and MANOVA (T. de 
Hotelling) to compare antioxidant capacity in normotensive rabbits and in OHT 














The figure 1 shows the antioxidant capacity of normotensive rabbits and 
OHT after and before the application of CLL. The antioxidant capacity of 
normotensive rabbits increased to a maximum of 3087 ± 45 μM 
FeSO4.6H2O/mg protein at 4 hours instillation. A significant increase in 
antioxidant capacity as a function of time was also observed in hypertensive 
rabbits (240 ± 8 μM FeSO4.6H2O/mg protein). The antioxidant capacity in the 
aqueous humor of hypertensive rabbits was ten times lower than in 
normotensive rabbits.  
  
Insert Figure 1  
 
Discussion 
Numerous studies have shown that RL production and subsequent 
damage usually increase with age, and therefore plays an important role in 
pathologies that appear with aging. Advanced age is a risk factor for glaucoma, 
and IOP appears to increase with age. In consequence, patients with glaucoma 
are genetically more prone to free-radical damage. Although the most important 
pathological factor for the progression of glaucoma is IOP increment, there are 
other factors such as the reduction of antioxidant capacity and increased free 
radicals, which may also play an important role in the progression of glaucoma 
[14]. 
A balance between free radical production and antioxidant potential 
occurs under normal physiological conditions, and oxidative stress begins its 
deleterious effect at the same time to the antioxidant effect decreases. Altered 
antioxidant mechanisms and increased markers of oxidative stress such as 
DNA oxidation, protein carbonyl formation and lipid peroxidation has been 
documented in glaucoma patients. 
The antioxidant status of a biological sample could be regarded as an 
indicator of oxidative stress: a decrease in the antioxidant capacity of body 
fluids may be the consequence of increased oxidative processes. We attempted 
to characterize the total antioxidant capacities of aqueous humor in 
normotensive and hypertensive rabbits. Our results suggest that hypertensive 
rabbits had significantly lower levels of antioxidant capacity in aqueous humor. 












pathogenesis of POAG and although their results were obtained in the aqueous 
humor of glaucoma patients, they coincide with ours [15]. 
Overall, these data indicates that altering the redox state contributes to 
the development of glaucoma, although the mechanisms by which oxidative 
stress triggers this event have not been fully elucidated. 
Although the main pharmacological approach to glaucoma treatment is to 
decrease IOP, therapeutic interventions aiming to reduce in vivo oxidative 
stress seem to be useful in patients suffering from the disease. In spite of all 
reported experimental data, there is still incomplete knowledge with which to 
understand whether free radical generation is a primary or a secondary event in 
glaucomatous neurodegeneration. 
Vitamin C due to its aqueous solubility can only be used topically for 
superficial ocular lesions. Amphiphilic derivatives of ascorbic acid-vitamin C 
(ASCn) have demonstrated the ability to form supramolecular aggregates 
resembling CLL and improve the lipids solubility and therefore improves the 
permeability through the ocular membranes, and can be used as a possible tool 
of ocular neuroprotection for pathologies such as glaucoma [9]. 
This derivative, which is capable of forming lamellar CLL, according to 
previous results, was able to modify the antioxidant capacity of the aqueous 
humor when was topically applied to the eye surface. An increase of antioxidant 
capacity was observed in normotensive and hypertensive rabbits which could 
be attributed to an increase in the concentrations of AA (such as laurate) in the 
anterior chamber. This behavior would be indicative of the potential utility of 
ASC12 in the treatment or prophylaxis of several ocular diseases, including 
glaucoma. 
An effective synergistic effect is expected through the incorporation of 
antiglaucomatous drugs into this drug delivery system. COA-ASC12 has also 
demonstrated drug permeation enhancement when administered onto ocular 
mucosa [9,16]. This strategy is being evaluated in our working group. 
 
Future Perspective 
The current treatment of glaucoma is focused only on decreasing the 












topical hypotensive treatment with a topical ocular neuroprotective treatment. 
The nanostructures presented here would become a smart choice in this field. 
 
Executive summary 
Glaucoma disease and current treatment 
● Glaucoma is the second cause of global irreversible blindness.  
● Conventional glaucoma treatment aims to lower IOP.  
● The oxidative stress involved in glaucoma evolution is not currently 
treated.  
 
Proposed delivery device 
● ASC12, has the capacity to form CLL and keeps its free radical trapping 
power. 
● The CLL of ASC12 were able to increase the antioxidant capacity in 
experimental rabbits 
● This type of nanostructures could be used for a more efficient 




The article has been reviewed by a proofreading service by native speaking 














1. Pinazo-Durán MD, Gallego-Pinazo R, García-Medina JJ, Zanón-Moreno V, 
Nucci C, Dolz-Marco R, et al. Oxidative stress and its downstream signaling in 
aging eyes. Clin Interv Aging. 2014; 11(9): 637-52. 
2. Umapathy A, Donaldson P, Lim J. Antioxidant delivery pathways in the 
anterior eye. Biomed Res Int. 2013:207250.  
3. Kang JH, Pasquale LR, Willett W, Rosner B, Egan KM, Faberowski N, et al. 
Antioxidant intake and primary open angle glaucoma: A prospective study. Am J 
Epidemiol. 2003;158(4):337–346. 
4. Ramdas WD, Schouten JSAG, Webers CAB. The Effect of Vitamins on 
Glaucoma: A Systematic Review and Meta-Analysis. Nutrients. 2018 16;10(3). 
5. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004; 
22(363):1711-20. 
6. Osborne NN, Wood JP, Chidlow G, Bae JH, Melena J, Nash MS. Ganglion 
cell death in glaucoma: what do we really know? Br J Ophthalmol. 1999; 
83(8):980-6.  
7. Huang W, Dobberfuhl A, Filippopoulos T, Ingelsson M, Fileta JB, Poulin NR, 
Grosskreutz CL. Transcriptional up-regulation and activation of initiating 
caspases in experimental glaucoma. Am J Pathol. 2005; 167(3): 673-81. 
8. Zanon-Moreno V, Marco-Ventura P, Lleo-Perez A, Pons-Vazquez S, Garcia-
Medina JJ, Vinuesa-Silva I, et al. Oxidative stress in primary open-angle 
glaucoma. J Glaucoma. 2008; 17(4): 263-8. 
9.Tártara LI, Quinteros DA, Saino V, Allemandi DA, Palma SD. Improvement of 
acetazolamide ocular permeation using ascorbyl laurate nanostructures as drug 
delivery system. J Ocul Pharmacol Ther. 2012; 28(2): 102-9. 
10. Palma SD, Maletto B, Lo Nostro P, Manzo RH, Pistoresi-Palencia MC, 
Allemandi DA. Potential use of ascorbic acid-based surfactants as skin 
penetration enhancers. Drug Dev Ind Pharm. 2006 Aug;32(7):821-7. 
11.Tártara LI, Leavi S, Campana V, Allemandi D, Palma S. Comparison of two 
experimental models of glaucoma in rabbits. Rev Fac Cien Med Univ Nac 
Cordoba. 2018; 75(1): 25-31.  
12. Benzie IF, Strain JJ. Ferric reducing/antioxidant power assay: direct 
measure of total antioxidant activity of biological fluids and modified version for 
simultaneous measurement of total antioxidant power and ascorbic acid 
concentration. Methods Enzymol. 1999;299:15-27. 
13. Jampel HD. Determination of protein concentration in aqueous humor. J 
Glaucoma. Spring 1994; 3(1): 5-11. 
14. Ergan E, Ozturk F, Beyazyildiz E, Elgin U, Sen E, Cankaya AB, et al. 
Oxidant/antioxidant balance in the aqueous humor of patients with glaucoma. 
Int J Ophthalmol. 2016; 9(2): 249-52. 
15. Ferreira SM, Lerner SF, Brunzini R, Evelson PA, Llesuy SF. Oxidative 
stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol. 
2004; 137(1):62-9. 
16. Palma SD, Ullio Gamboa GV, Allemandi DA. Vitamin C based 
Nanostructures:  Potential  utility  in  ocular  and  transdermal  therapy. J 




























Figure 1: Antioxidant capacity determined by the FRAP method in aqueous 
humor of normotensive and OHT rabbits treated and untreated with COA-
ASC12. Control values represent rabbits without treatment with COA-ASC12. 
The line with circles represents the antioxidant capacity of the normotensive 
rabbits while the line with triangles  indicates the antioxidant capacity of the 
hypertensive rabbits. The mean and standard deviation values of antioxidant 
capacity, expressed in µM FeSO4.6H20/mg protein, were compared statistically 
with a significance level of p < 0.05.  
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